Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Evaluation of metabolic changes involved in glioblastoma relapse
研究概览
简要总结
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
详细描述
Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months.
Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant.
The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age > 18 years
- •surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
排除标准
- •systemic therapy received for non-glioblastoma tumor
研究组 & 干预措施
Patients operated for primary and recurrent glioblastoma
Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
干预措施: Relapsed glioblastoma (Biological)
结局指标
主要结局
Evaluation of metabolic changes involved in glioblastoma relapse
时间窗: Up to 2 years after the start of the study
Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample
次要结局
- Overall survival(From date of the second surgery until the date of death from any cause, assessed up to 5 years)
- Progression-free survival(From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)